Oculis Holding AG
OCS20.690USD
+0.210+1.03%
收盘 12/24, 13:00（美东）报价延迟15分钟
1.16B总市值
亏损市盈率 TTM
关于 Oculis Holding AG 公司
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Oculis Holding AG简介
公司代码OCS
公司名称Oculis Holding AG
上市日期Mar 03, 2023
CEOSherif (Riad)
员工数量49
证券类型Ordinary Share
年结日Mar 03
公司地址Bahnhofstrasse 20
城市ZUG
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Switzerland
邮编6300
电话41417113960
网址https://oculis.com/
公司代码OCS
上市日期Mar 03, 2023
CEOSherif (Riad)
Oculis Holding AG公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Martijn Kleijwegt
Mr. Martijn Kleijwegt
Independent Director
Independent Director
470.97K
--
Mr. Pall Ragnar Johannesson
Mr. Pall Ragnar Johannesson
Chief Business Officer
Chief Business Officer
268.83K
+7.87%
Ms. Sylvia Cheung, CPA
Ms. Sylvia Cheung, CPA
Chief Financial Officer
Chief Financial Officer
72.06K
+7.86%
Ms. Geraldine O'Keeffe
Ms. Geraldine O'Keeffe
Independent Director
Independent Director
20.59K
--
Mr. Robert K. Warner
Mr. Robert K. Warner
Independent Director
Independent Director
--
--
Mr. Arshad M. Khanani, M.D.
Mr. Arshad M. Khanani, M.D.
Independent Director
Independent Director
--
--
Mr. Anthony A. (Tony) Rosenberg
Mr. Anthony A. (Tony) Rosenberg
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Riad Sherif, M.D.
Dr. Riad Sherif, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Christina M. Ackermann
Ms. Christina M. Ackermann
Independent Director
Independent Director
--
-100.00%
Mr. Lionel Carnot
Mr. Lionel Carnot
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Martijn Kleijwegt
Mr. Martijn Kleijwegt
Independent Director
Independent Director
470.97K
--
Mr. Pall Ragnar Johannesson
Mr. Pall Ragnar Johannesson
Chief Business Officer
Chief Business Officer
268.83K
+7.87%
Ms. Sylvia Cheung, CPA
Ms. Sylvia Cheung, CPA
Chief Financial Officer
Chief Financial Officer
72.06K
+7.86%
Ms. Geraldine O'Keeffe
Ms. Geraldine O'Keeffe
Independent Director
Independent Director
20.59K
--
Mr. Robert K. Warner
Mr. Robert K. Warner
Independent Director
Independent Director
--
--
Mr. Arshad M. Khanani, M.D.
Mr. Arshad M. Khanani, M.D.
Independent Director
Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 12月2日 周二
更新时间: 12月2日 周二
持股股东
股东类型
持股股东
持股股东
占比
EQT Partners AB
10.21%
EQT Life Sciences
9.95%
Earlybird Venture Capital
4.40%
Pivotal Bioventure Partners Investment Advisor LLC
3.98%
BVCF Management, Ltd.
3.79%
其他
67.67%
持股股东
持股股东
占比
EQT Partners AB
10.21%
EQT Life Sciences
9.95%
Earlybird Venture Capital
4.40%
Pivotal Bioventure Partners Investment Advisor LLC
3.98%
BVCF Management, Ltd.
3.79%
其他
67.67%
股东类型
持股股东
占比
Venture Capital
23.74%
Private Equity
10.21%
Investment Advisor/Hedge Fund
3.17%
Corporation
2.96%
Individual Investor
2.75%
Investment Advisor
1.68%
Hedge Fund
0.55%
Research Firm
0.07%
Bank and Trust
0.05%
其他
54.82%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
49
16.42M
28.41%
+792.94K
2025Q2
51
19.48M
37.42%
+1.76M
2025Q1
51
19.44M
37.35%
+1.93M
2024Q4
86
15.00M
31.97%
-10.87M
2024Q3
87
16.29M
41.43%
-9.17M
2024Q2
88
16.63M
42.28%
-9.14M
2024Q1
91
16.14M
42.22%
-11.25M
2023Q4
93
17.20M
46.87%
-6.97M
2023Q3
92
16.51M
48.34%
-4.37M
2023Q2
91
16.72M
48.91%
-4.14M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
EQT Life Sciences
5.75M
10.99%
+425.53K
+7.99%
Dec 31, 2024
Earlybird Venture Capital
2.54M
4.86%
+2.54M
--
Dec 31, 2024
Pivotal Bioventure Partners Investment Advisor LLC
2.30M
4.4%
--
--
Jun 30, 2025
BVCF Management, Ltd.
2.19M
4.19%
+121.79K
+5.88%
Nov 27, 2024
abrdn Inc.
1.25M
2.39%
--
--
Jun 30, 2025
Sherif (Riad M.D.)
644.75K
1.23%
-233.73K
-26.61%
Dec 31, 2024
Stefnir hf.
540.50K
1.03%
--
--
Aug 31, 2025
Nan Fung Life Sciences
514.70K
0.98%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
Simplify Propel Opportunities ETF
2.81%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.12%
Even Herd Long Short ETF
0%
Simplify Propel Opportunities ETF
占比2.81%
SPDR SSGA US Small Cap Low Volatility Index ETF
占比0.12%
Even Herd Long Short ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Oculis Holding AG的前五大股东是谁？
Oculis Holding AG 的前五大股东如下：
EQT Life Sciences持有股份：5.75M，占总股份比例：10.99%。
Earlybird Venture Capital持有股份：2.54M，占总股份比例：4.86%。
Pivotal Bioventure Partners Investment Advisor LLC持有股份：2.30M，占总股份比例：4.40%。
BVCF Management, Ltd.持有股份：2.19M，占总股份比例：4.19%。
abrdn Inc.持有股份：1.25M，占总股份比例：2.39%。
EQT Life Sciences持有股份：5.75M，占总股份比例：10.99%。
Earlybird Venture Capital持有股份：2.54M，占总股份比例：4.86%。
Pivotal Bioventure Partners Investment Advisor LLC持有股份：2.30M，占总股份比例：4.40%。
BVCF Management, Ltd.持有股份：2.19M，占总股份比例：4.19%。
abrdn Inc.持有股份：1.25M，占总股份比例：2.39%。
Oculis Holding AG的前三大股东类型是什么？
Oculis Holding AG 的前三大股东类型分别是：
EQT Partners AB
EQT Life Sciences
Earlybird Venture Capital
EQT Partners AB
EQT Life Sciences
Earlybird Venture Capital
有多少机构持有Oculis Holding AG(OCS)的股份？
截至2025Q3，共有49家机构持有Oculis Holding AG的股份，合计持有的股份价值约为16.42M，占公司总股份的28.41%。与2025Q2相比，机构持股有所增加，增幅为-9.01%。
哪个业务部门对Oculis Holding AG的收入贡献最大？
在--，--业务部门对Oculis Holding AG的收入贡献最大，创收--，占总收入的--%。
